| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―May―12 |
SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones |
GÖNÜL SAADET BATIBAY, EYÜP METİN |
| 2 |
[GO] |
2022―Dec―21 |
Design, synthesis, and greener pasture biological assessment of a novel nucleoside: 1-(α-D-ribofuranosyl)-6,7-difluoro-2-methyl-4-quinazolinone as an inhibitor of COVID-19 and Alzheimer's disease |
LAILA M. BREAK, ADIL A. GOBOURI, WAFA S. AL-HARTHI, MOHAMED HAGAR, NADIA S. ALKAFF, MUSA A. SAID |
| 3 |
[GO] |
2022―Oct―06 |
Synthesis, characterization, computational analyses, in silico ADMET studies, and inhibitory action against SARS-CoV-2 main protease (Mpro) of a Schiff base |
SONGÜL ŞAHİN, NECMİ DEGE |
| 4 |
[GO] |
2022―Jun―22 |
A systematic review of RdRp of SARS-CoV-2 through artificial intelligence and machine learning utilizing structure-based drug design strategy |
FARIHA IMTIAZ, MUSTAFA KAMAL PASHA |
| 5 |
[GO] |
2021―Dec―28 |
A Systematic Review of RdRp of SARS-CoV-2 through Artificial Intelligence and Machine Learning Utilizing Structure-Based Drug Design Strategy |
|
| 6 |
[GO] |
2021―Sep―17 |
Virtual screening, drug-likeness analysis and molecular docking study of potential severe acute respiratory syndrome coronavirus 2 main protease inhibitors |
|
| 7 |
[GO] |
2021―Mar―08 |
Synthesis and Molecular Docking Study of Novel COVID-19 Drug Candidates |
|
| 8 |
[GO] |
2020―Oct―06 |
Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: A molecular docking study |
|
